blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2245190

EP2245190 - IMPROVED ASSAY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  17.02.2023
Database last updated on 18.11.2024
FormerExamination is in progress
Status updated on  09.04.2022
Most recent event   Tooltip17.02.2023Application deemed to be withdrawnpublished on 22.03.2023  [2023/12]
Applicant(s)For all designated states
Biovator Technologies AB
P.O. Box 7710
103 95 Stockholm / SE
[2010/44]
Inventor(s)01 / MATTSSON, Karin
Jordgränd 46
S-192 74 Sollentuna / SE
02 / DOMEIKA, Kristina
Läby Solsäter 33
S-755 92 Uppsala / SE
 [2010/44]
Representative(s)(deleted)
[N/P]
Former [2010/44]Holmberg, Nils Anders Patrik, et al
Brann AB P.O. Box 171 92
104 62 Stockholm / SE
Application number, filing date08862968.818.12.2008
[2010/44]
WO2008EP67931
Priority number, dateWO2007EP6414418.12.2007         Original published format: PCT/EP2007/064144
SE2008000202023.09.2008         Original published format: SE 0802020
[2010/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009077602
Date:25.06.2009
Language:EN
[2009/26]
Type: A1 Application with search report 
No.:EP2245190
Date:03.11.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 25.06.2009 takes the place of the publication of the European patent application.
[2010/44]
Search report(s)International search report - published on:EP25.06.2009
ClassificationIPC:C12Q1/68, G01N33/68
[2010/44]
CPC:
C12Q1/6883 (EP); G01N33/5047 (EP); G01N33/6863 (EP);
G01N33/6869 (EP); G01N2333/525 (EP); G01N2333/54 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/44]
TitleGerman:VERBESSERTES TESTVERFAHREN[2010/44]
English:IMPROVED ASSAY[2010/44]
French:ESSAI PERFECTIONNÉ[2010/44]
Entry into regional phase06.07.2010National basic fee paid 
06.07.2010Designation fee(s) paid 
06.07.2010Examination fee paid 
Examination procedure06.07.2010Examination requested  [2010/44]
06.09.2010Amendment by applicant (claims and/or description)
01.12.2010Despatch of a communication from the examining division (Time limit: M04)
01.04.2011Reply to a communication from the examining division
02.03.2022Application deemed to be withdrawn, date of legal effect  [2023/12]
21.09.2022Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2023/12]
Public notification(s)Noting of loss of rights pursuant to Rule 112(1) EPC (EPO Form 2524 dated 19/07/2022)
Biovator Technologies AB
P.O. Box 7710
103 95 Stockholm / SE
[2022/38]
Communication pursuant to Rule 142 EPC (Resumption of proceedings under Rule 142(2) EPC dated 16.04.2021)
Biovator Technologies AB
P.O. Box 7710
103 95 Stockholm / SE
[2021/26]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.12.2010
Fees paidRenewal fee
17.12.2010Renewal fee patent year 03
20.12.2011Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
01.09.202105   M06   Not yet paid
01.09.202106   M06   Not yet paid
01.09.202107   M06   Not yet paid
01.09.202108   M06   Not yet paid
01.09.202109   M06   Not yet paid
01.09.202110   M06   Not yet paid
01.09.202111   M06   Not yet paid
01.09.202112   M06   Not yet paid
01.09.202113   M06   Not yet paid
31.12.202114   M06   Not yet paid
31.12.202215   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Stay/Interruption04.01.2012Interruption of proceedings. Reason: legal prevention of applicant[2012/11]
01.09.2021Resumption of proceedings[2021/09]
04.01.2012Interruption of proceedings. Reason: legal prevention of applicant[2021/09]
Cited inInternational search[DA]WO9716732  (ANDERSSON BIRGER [SE]);
 [DA]WO2007032743  (BIOVATOR TECHNOLOGIES AB [SE], et al);
 [A]WO0129562  (NOVOZYMES AS [DK])
 [X]  - DJEU J Y ET AL, "INTERFERON-GAMMA-INDUCED ALTERATIONS OF MONOCYTE SUSCEPTIBILITY TO LYSIS BY AUTOLOGOUS LYMPHOKINE-ACTIVATED KILLER LAK CELLS", INTERNATIONAL JOURNAL OF CANCER, (1988), vol. 42, no. 3, ISSN 0020-7136, pages 449 - 454, XP002521503 [X] 15,19 * RESULTS: Effect of various cytokines on susceptibility of monocytes to LAK lysis *

DOI:   http://dx.doi.org/10.1002/ijc.2910420323
 [X]  - KIM SANGWON ET AL, "Effects of interferon-gamma and lipopolysaccharide on macrophage iron metabolism are mediated by nitric oxide-induced degradation of iron regulatory protein 2", JOURNAL OF BIOLOGICAL CHEMISTRY, (20000303), vol. 275, no. 9, ISSN 0021-9258, pages 6220 - 6226, XP002521504 [X] 15,19 * RESULTS: LPS/IFN-gamma Activates IRP-1 but Decreases RNA Binding of IRP-2 and Its Protein Levels *

DOI:   http://dx.doi.org/10.1074/jbc.275.9.6220
 [X]  - WERNER-FELMAYER G ET AL, "NEOPTERIN FORMATION AND TRYPTOPHAN DEGRADATION BY A HUMAN MYELOMONOCYTIC CELL LINE THP-1 UPON CYTOKINE TREATMENT", CANCER RESEARCH, (1990), vol. 50, no. 10, ISSN 0008-5472, pages 2863 - 2867, XP002521505 [X] 15,19 * MATERIALS AND METHODS: Cell Culture *
 [A]  - WIRLEITNER BARBARA ET AL, "Monocyte-derived dendritic cells release neopterin.", JOURNAL OF LEUKOCYTE BIOLOGY, (200212), vol. 72, no. 6, ISSN 0741-5400, pages 1148 - 1153, XP002477263
by applicantSE506533
 WO9716732
    - M. PALLARDYET, "In vitro evaluation of drug-induced toxic effects on the immune system as assessed by proliferative assays and cytokine production", EUR. CYTOKINE NET., vol. 2, no. 3, pages 201 - 206
 WO2006SE50336
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.